Uncommon Presentation and Therapeutic Strategies in Pediatric Relapsed/Refractory ALK-Positive ALCL
This case illustrates the clinical challenges of treating ALK-positive ALCL with concurrent HLH and highlights the role of targeted therapies. As molecular understanding of ALCL increases, integrating novel targeted agents may improve outcomes, particularly in relapsed or high-risk disease.
Authors
- Miriam B. Garcia (ORCID: https://orcid.org/0000-0002-2978-2267)
- David McCall (ORCID: https://orcid.org/0000-0003-2297-9670)
- Amber Gibson (ORCID: https://orcid.org/0000-0002-9146-4702)
- Maria D Frost
- Luis Malpica
- Michael Roth
- Samanta Catueno
- Cesar Nunez
- Branko Cuglievan
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Pediatric Oncology Group (CA)
- Maryland Oncology Hematology (US)
- Palmetto Hematology Oncology (US)
Publication Details
- Journal
- Journal of Pediatric Hematology/Oncology
- Published
- 2026-03-02
- DOI
- https://doi.org/10.1097/mph.0000000000003179
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00